2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2407

New Onset of Uveitis in Non-Methotrexate Group, Methotrexate Group and Etanercept Group in Juvenile Idiopathic Arthritis
Abstract Number: 699

New Onset/Recurrence of Inflammatory Arthralgia/Spondyloarthritis in Patients Treated with Vedolizumab for Intestinal Bowel Disease
Abstract Number: 1464

Newer Generation Cyclic Citrullinated Peptide (CCP) 3.1 Assay in the Diagnosis of Rheumatoid Arthritis
Abstract Number: 2014

Next Generation Sequencing Analysis of Familial Haemophagocytic Lymphohistiocytosis (HLH) Related Genes in Macrophage Activation Syndrome (MAS) and Secondary HLH (sHLH)
Abstract Number: 2851

NF-Κappa b Signaling in the Myeloid Cell Lineage Drives the Pathogenesis of Immune-Mediated Nephritis
Abstract Number: 2459

Nivolumab-Induced Synovial Tissue T Cell Infiltration, Sustained PD1 Occupancy and Resolution of Severe Synovitis with Infliximab Therapy
Abstract Number: 1552

No Effect of Concomitant Glucocorticoid Therapy on Efficacy and Safety of Tocilizumab Monotherapy Found in Rheumatoid Arthritis Clinical Trials
Abstract Number: 340

No Improvement in Time to Biopsy and Therapy in Lupus Nephritis Patients over Two Decades
Abstract Number: 831

No More HCV RNA in Serum and Cryoprecipitate in Patients with Persisting HCV-Cryoglobulinemia Vasculitis after Daa-Induced Sustained Virological Response
Abstract Number: 814

NON Diffuse SSc, Peripheral Neuropathy, Concomitant Sjogren Syndrome and ANTI-RNA Polymerase III Represent Risk Factors for the Higher Frequency of Cancer in a Large Single Cohort of Patients with Systemic Sclerosis
Abstract Number: 1813

Non-Aphthous Beginning As an Independent Risk Factor for the Course of Behçet’s Disease
Abstract Number: 2238

Non-Coding Urate-Associated Variants Function in a Conserved Lincrna Regulatory Domain That Alters MAF transcription
Abstract Number: 1160

Non-Elderly Adults Who Have Never Seen a Health-Care Provider for Chronic Joint Symptoms- Updated Results from National Health Interview Survey 2015
Abstract Number: 123

Non-Hematopoietic Derived TNF Drives Pulmonary Vasculopathy: A New Model of CTD-Associated Pulmonary Hypertension
Abstract Number: 508

Non-Invasive Evaluation of Left Atrial Pressure in Hispanic Patients with Rheumatoid Arthritis: A Case-Control Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].